Edition:
United Kingdom

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

157.15DKK
18 Jun 2019
Change (% chg)

-- (--)
Prev Close
kr.157.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
148,415
52-wk High
kr.204.30
52-wk Low
kr.117.75

Latest Key Developments (Source: Significant Developments)

Bavarian Nordic Says Share Buy-Back Program Announced And Initiated On May 22, 2019, Terminated
Monday, 3 Jun 2019 

June 3 (Reuters) - Bavarian Nordic A/S ::SHARE BUY-BACK PROGRAM ANNOUNCED AND INITIATED ON MAY 22, 2019, HAS NOW BEEN TERMINATED.  Full Article

Bavarian Nordic Jan-March EBIT Loss Narrows To DKK 104 Mln
Wednesday, 22 May 2019 

May 22 (Reuters) - Bavarian Nordic A/S ::REG-BAVARIAN NORDIC ANNOUNCES INTERIM RESULTS FOR THE FIRST THREE MONTHS OF 2019.OUTLOOK FOR 2019 MAINTAINED.REVENUE GENERATED FOR THREE MONTHS ENDING MARCH 31, 2019 WAS DKK 127 MILLION/USD 19 MILLION (DKK 11 MILLION/USD 2 MILLION IN FIRST THREE MONTHS OF 2018).JAN-MARCH INCOME BEFORE INTEREST AND TAX (EBIT) WAS A LOSS OF DKK 104 MILLION/USD 16 MILLION (LOSS OF DKK 173 MILLION/USD 26 MILLION IN FIRST THREE MONTHS OF 2018).  Full Article

Bavarian Nordic FY EBIT Swings To Loss DKK 354.5 Million
Thursday, 21 Mar 2019 

March 21 (Reuters) - Bavarian Nordic A/S ::REG-BAVARIAN NORDIC ANNOUNCES ANNUAL REPORT 2018.FY REVENUE DKK 500.6 MILLION VERSUS DKK 1.37 BILLION YEAR AGO.IN 2019, WE EXPECT REVENUE OF ABOUT DKK 600 MILLION AND A LOSS BEFORE INTEREST AND TAX (EBIT) OF ABOUT DKK 360 MILLION.FY EBIT LOSS DKK 354.5 MILLION VERSUS PROFIT DKK 353.2 MILLION YEAR AGO.CASH PREPAREDNESS AT YEAR-END IS EXPECTED TO AMOUNT TO APPROXIMATELY DKK 1,600 MILLION.  Full Article

Bavarian Nordic Announces FDA Delay In The Review Of The Application For MVA-BN Smallpox Vaccine
Monday, 11 Mar 2019 

March 11 (Reuters) - Bavarian Nordic A/S ::BAVARIAN NORDIC ANNOUNCES FDA DELAY IN THE REVIEW OF THE BIOLOGICS LICENSE APPLICATION FOR MVA-BN SMALLPOX VACCINE.DELAY WILL NOT IMPACT COMPANY'S OPERATIONS.CO'S BIOLOGICS LICENSE APPLICATION MAINTAINS PRIORITY REVIEW STATUS WITH FDA.BAVARIAN NORDIC WOULD STILL BE ELIGIBLE TO RECEIVE A PRIORITY REVIEW VOUCHER WHEN MVA-BN IS APPROVED.BAVARIAN NORDIC- FDA HAS ASSESSED THAT DUE TO AMOUNT OF DATA SUBMITTED DURING REVIEW NEEDS MORE TIME, HAS EXTENDED TARGET PDUFA ACTION DATE TO SEPT 2019.  Full Article

Bavarian Nordic: U.S. Government Exercises $44 Mln Option Under Contract For Smallpox Vaccine
Friday, 18 Jan 2019 

Jan 18 (Reuters) - Bavarian Nordic A/S ::REG-BAVARIAN NORDIC ANNOUNCES EXERCISE OF USD 44 MILLION OPTION BY THE U.S. GOVERNMENT UNDER CONTRACT FOR FREEZE-DRIED MVA-BN® SMALLPOX VACCINE.MAJORITY OF THIS CONTRACT OPTION IS EXPECTED TO BE REVENUE RECOGNISED IN 2019 AND 2020..OPTION WILL COVER QUALIFICATION OF NEW FILL-FINISH FACILITY, CURRENTLY BEING ESTABLISHED AT COMPANY'S MANUFACTURING SITE IN DENMARK.  Full Article

Bavarian Nordic Q3 EBIT Falls To DKK 19.0 Million
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Bavarian Nordic A/S ::REG-BAVARIAN NORDIC ANNOUNCES INTERIM RESULTS FOR THE FIRST NINE MONTHS OF 2018.OUTLOOK FOR 2018 MAINTAINED.REVENUE GENERATED FOR NINE MONTHS ENDING SEPTEMBER 30, 2018 WAS DKK 319 MILLION/USD 50 MILLION.Q3 REVENUE DKK 221.7 MILLION VERSUS DKK 734.3 MILLION YEAR AGO.Q3 2018, PRODUCTION COSTS WERE DKK 80 MILLION (DKK 99 MILLION).Q3 EBIT DKK 19.0 MILLION VERSUS DKK 432.0 MILLION YEAR AGO.  Full Article

Orexo Appoints Joseph Defeo As New CFO
Wednesday, 24 Oct 2018 

Orexo Ab ::OREXO APPOINTS JOSEPH DEFEO AS NEW CFO.APPOINTS JOSEPH DEFEO AS COMPANY'S NEW CHIEF FINANCIAL OFFICER (CFO) FROM NOVEMBER 1, 2018.JOSEPH DEFEO WILL SUCCEED HENRIK JUUEL WHO WILL JOIN DANISH COMPANY BAVARIAN NORDIC A/S AS THEIR NEW CFO..  Full Article

Bavarian Nordic Q2 EBIT Swings To Loss Of DKK 107 Million
Thursday, 16 Aug 2018 

Aug 16 (Reuters) - BAVARIAN NORDIC A/S ::REG-BAVARIAN NORDIC ANNOUNCES FIRST HALF 2018 RESULTS.Q2 REVENUE DKK 86.3 MILLION VERSUS DKK 397.3 MILLION YEAR AGO.Q2 EBIT LOSS DKK 107.0 MILLION VERSUS PROFIT DKK 102.3 MILLION YEAR AGO.SAYS FINANCIAL RESULTS WERE IN LINE WITH OUR EXPECTATIONS AND OUTLOOK IS MAINTAINED.  Full Article

Reg-Bavarian Nordic Announces Positive Data From Phase 2 Extension Study Of Its Universal Rsv Vaccine
Wednesday, 8 Aug 2018 

Bavarian Nordic A/S ::REG-BAVARIAN NORDIC ANNOUNCES POSITIVE DATA FROM PHASE 2 EXTENSION STUDY OF ITS UNIVERSAL RSV VACCINE.SAYS ANNUAL BOOSTER OF MVA-BN-RSV INDUCED A BROAD AND ROBUST IMMUNE RESPONSE.COMPARED TO PRE-VACCINATION LEVELS 1 YEAR BEFORE, BOOST EFFECT WAS IN RANGE OF A 1.5 TO 3-FOLD INCREASE.BAVARIAN NORDIC - EXTENSION STUDY DEMONSTRATED THAT IN AT LEAST 60% OF SUBJECTS BROAD ANTIBODY RESPONSES AGAINST RSV WERE DURABLE.POSITIVE CLINICAL RESULTS WILL BE KEY IN DISCUSSING DESIGN OF PHASE 3 WITH FDA AT A MEETING PLANNED FOR LATER THIS YEAR.  Full Article

Bavarian Nordic Q1 EBIT Loss Widens To DKK 173 Million
Thursday, 24 May 2018 

May 24 (Reuters) - BAVARIAN NORDIC A/S ::REG-BAVARIAN NORDIC ANNOUNCES INTERIM RESULTS FOR THE FIRST THREE MONTHS OF 2018.OUTLOOK FOR 2018 MAINTAINED.Q1 EBIT LOSS DKK 173 MILLION VERSUS LOSS DKK 3 MILLION YEAR AGO.OUTLOOK FOR 2018 MAINTAINED.Q1 REVENUE DKK 11 MILLION VERSUS DKK 198 MILLION YEAR AGO."FINANCIAL RESULTS FOR Q1 WERE IN LINE WITH OUR EXPECTATIONS".  Full Article

BRIEF-Bavarian Nordic REPORTS Positive Result From Phase 2 Trial Evaluating BN-Brachyury In Chordoma

* REPORTED ON WEDNESDAY POSITIVE RESULT FROM ONGOING PHASE 2 TRIAL EVALUATING BN-BRACHYURY IN CHORDOMA